Sunshine Biopharma Reports 4.1% Revenue Growth to $36.3M, Launches Nine Generics
Sunshine Biopharma posted $36.3M revenue in fiscal 2025, up 4.1% from $34.9M, with net loss of $5.98M vs $5.13M. The company raised $2.46M via direct offering, launched nine generics and advanced PLpro protease inhibitors while targeting $2M–3M expense cuts in 2026.
1. Fiscal 2025 Financial Results
Sunshine Biopharma reported $36.3M revenue, up 4.1% from $34.87M in 2024, with gross profit of $12.26M and net loss of $5.98M versus $5.13M a year earlier; general and administrative expenses rose to $18.48M, driven by a $1.75M impairment charge.
2. Capital Raise and Generics Expansion
The company raised $2.46M through a registered direct offering to support sales operations and launched nine new generic prescription drugs across oncology, cardiovascular health, central nervous system disorders and antimicrobials, bringing its Canadian portfolio to 71 drugs with 12 more planned in 2026.
3. Antiviral R&D Progress
Sunshine advanced its proprietary PLpro protease inhibitor series, demonstrating dose-dependent antiviral activity in SARS-CoV-2-infected mice, strong cellular potency and favorable pharmacokinetics, while progressing a K1.1 mRNA-LNP therapeutic candidate targeting liver cancer.
4. 2026 Cost-Reduction and Growth Outlook
In January 2026 the company initiated cost-reduction measures aimed at cutting general and administrative expenses by $2M–$3M to drive near-term profitability, alongside continued expansion of its generic portfolio and advancement of proprietary drug programs.